Since our initial purpose was to validate c-Rel as a potential therapeutic target, we utilized a retrovirus to deliver siRNA, as these agents have a higher transduction efficiency in tumor cell lines and primary cells, which are often resistant to conventional DNA transfection methods. The gene discussed is REL; the disease is neoplasm.